Malaysia Biotech Sector Expects Slower Growth This Year
This article was originally published in PharmAsia News
Executive SummaryMalaysia's Biotech Corp says it expects the country's biotech sector to grow at a slower rate this year because of the global economic situation. CEO Datuk Iskander Mizal Mahmood said, however, he is optimistic Malaysia's biotech industry will continue to be resilient. The government agency noted the sector had 18 percent growth in 2008, but Iskandar said it would not be realistic to expect that rate this year. He said Biotech Corp expects to shepherd about the same number of new companies in setting up businesses this year, usually 50 to 55. (Click here for more
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.